Emerging technologies focused on
Improving Patient Outcomes
for cost effective healthcare

 

Our Mission

Although there has been great advances in the understanding and treatment of cancer, this disease today is largely detected and diagnosed with the same procedures and technology that has been used for generations. The same is true for measuring an individual’s response to therapy. These methods are inefficient, painful and expensive. NuView wants to change this. We are developing a compelling and innovative way to detect, diagnose and personalize the treatment of cancer.
Read the ebook:
Cancer Specific Molecular Biomarkers

Strong IP Pipeline

  • Urine screen to detect prostate and bladder cancer
  • Imaging agent to diagnose prostate and breast cancer
  • Imaging agent to assess tumor response to therapy

DEVELOPING BREAKTHROUGH TECHNOLOGIES

  • Replace PSA testing with accurate and early detection
  • Eliminate invasive diagnostic procedures by visualizing disease
  • Personalize therapies with rapid assessment of tumor response

video-play

What is PET Imaging?

Images produced from new medical technologies that incorporate PET (positron emission tomography) are similar to a weather map you see on your local news.

Play Video

Read More

img-portfolio

Our NLS-VPAC1 Technology Platform

Our patented imaging agent binds to a receptor (called VPAC1) on the surface of many cancer cells.   We are utilizing this technology to create a urine screen to detect prostate/bladder cancer and an imaging agent to transform the diagnosis of breast and prostate cancer.

Learn more

img-shopping

Our NLS-FMAU Imaging Agent

Our patented imaging agent directly visualizes the cellular proliferation of a tumor.  We are developing this product to rapidly assess an individual’s response to cancer therapy.

Learn more

Market Readiness Progress (at 100%)

NLS-VPAC1 - Prostate / Bladder Cancer Urine Screen @ Analytical Validation

NLS-VPAC1 - Breast Cancer Imaging @ Phase 1

NLS-VPAC1 - Prostate Cancer Imaging @ Phase 1 Ongoing

NLS-FMAU - Cancer Tumor Treatment Planning and Therapy Response @ Phase 1 Ongoing

Management Team

  • Paul Crowe

    Chairman & CEO

    About Paul Crowe

    Mr. Crowe is the founder of NuView Life Sciences and has served as Chairman and Chief Executive Officer since 2005. Mr. Crowe’s experience includes early-stage company development, strategic planning, capital formation, M&A, and public offerings. Over the past 40 years, Mr. Crowe has commercialized novel medical imaging technologies, such as diagnostic ultrasound with Philips Medical Systems, magnetic resonance imaging (MRI) with Diasonics NMR and positron emission tomography (PET) with Mobile PET Systems. Mr. Crowe developed several medical service provider businesses utilizing the technologies described above building high-performance management, sales and operations teams to drive technology adoption and revenue growth.

  • Peter S. Conti, MD

    Medical Director

    About Peter S. Conti, MD

    Dr. Conti has served as the Company’s Medical Director and Director of the Company since October 2004.  Dr. Conti is a Professor of Radiology, Pharmacy, and Biomedical Engineering at the University of Southern California, as well as Director of its Positron Imaging Science Center and Clinic. Dr. Conti received his medical degree from Cornell University and completed his residency in Diagnostic Radiology and fellowship in Nuclear Medicine at The Johns Hopkins Medical Institution. He is board-certified in both Diagnostic Radiology and Nuclear Medicine. Dr. Conti currently serves on the Board of Directors and is a past-president of the Society of Nuclear Medicine (SNM). Dr Conti also serves on a number of committees for the SNM that is focused on the development of the PET technology and its applications in medicine, including those involving government and regulatory affairs.

  • Thomas McCausland

    Director

    About Thomas McCausland

    Mr. McCausland joined the Company as a Director in October 2007. Over Mr. McCausland’s 40-year business career, he has served in senior executive positions with Westinghouse Electric Corporation and Siemens. From 1997 through 2006, he served as President of the Siemens Medical Customer Solutions Group and grew revenues from $1 billion to over $4 billion during his tenure. In addition to serving as an advisor to the Radiological Society of North America and several other healthcare companies, Mr. McCausland also served as chairman of the Siemens Foundation dedicated to improving math and science education in high schools.

  • Mark Godsy

    Director

    About Mark Godsy

    Mark Godsy serves as an advisor of Exro Technologies Inc., has been the CEO of Collective Protection Inc. since August 2002, and served as the chairman of Unity Wireless Corp. from 1993 to 1998 and its CEO from February 2000 to November 2000. He served as the secretary of Unity Wireless Corp.’s subsidiary from 1993 to 1995 and also from May 1997 to November 1998.

    Mark is an experienced entrepreneur working in the areas of corporate development and venture capital. A member of the BC Law Society, he practiced law for five years before entering business and co-founding two successful companies, ID Biomedical Corp. and Angiotech Pharmaceuticals Ltd., both of which are leading Canadian biotechnology firms. Mark served as CEO of ID Biomedical Corp. from 1991 to 1996. After semi-retirement since 1996, in 2001 Mark served as the CEO of Medcell Biologies Inc. He has also served as the chairman of Wescorp Energy Inc., and serves as a member of the business advisory board of biOasis Technologies Inc. Mark is a graduate of the University of British Columbia and received his law degree from McGill University

  • Michael Nobel PH.D.

    Director

    About Michael Nobel PH.D.

    Michael Nobel participated in the introduction of magnetic resonance imaging in 1980 and remained in that field for 26 years. Today he is chairman or board member of seven international companies in diagnostics, treatment and information systems in the field of medicine.

    For 15 years Michael Nobel represented the Nobel family as vice chairman and chairman of its board of directors. He is founder and chairman of the Nobel Sustainable Trust.  He is chairman or board member of eight non-for-profit organizations in the field of youth education and development and peace and conflict resolution.

    Michael Nobel was visiting professor at the Frontier Research Institute at the Tokyo Institute of Technology between 2007 and 2012. He is currently a senior fellow at the Centre for the Study of World Civilizations at Tokyo Tech and a guest professor at Seisa University.

    In 2005 in Jerusalem he received the Albert Einstein Medal for Outstanding Achievements in Life Sciences and Technology and in 2006 the International Order of Perfection in Moscow. In 2013 he received the Order of Duty and Honor from the United Nations Council for Public Awards and the Gold Medal from the IINC in Tambov, Russia. The World Federation of Consuls presented him its Order of Merit in 2014.

    Michael Nobel obtained a doctorate at the University of Lausanne in psycho-pedagogy.

  • Maury DeWald, CPA

    Director

    About Maury DeWald, CPA

    Maurice DeWald has served as the Chairman and CEO of Verity Financial Group, Inc., since 1992, where the primary focus has been in healthcare and technology sectors. He also serves as a director of public companies Healthcare Trust of America, Inc. and Targeted Medical Pharma, Inc. and as a non-executive Chairman of public company Integrated Healthcare Holdings, Inc. DeWald previously served as a director of Tenet Healthcare Corporation, ARV Assisted Living, Inc., Quality Systems, Inc. and Integrated Healthcare Holdings, Inc. From 1962 to 1991, DeWald was employed by KPMG, LLP, where he served at various times as an audit partner, a member of their board of directors, as well as managing partner of the Los Angeles office.

  • Thomas Brown

    Vice President Finance

    About Thomas Brown

    Mr. Brown has over 40 years of business and financial experience in the analysis, structuring and sourcing of capital, valuation, repositioning/restructuring and the management of financial/operating assets, as well as, businesses. Mr. Brown is the founding partner of three investment-banking firms, a private equity firm, and two investment management firms. Mr. Brown has served as the CFO of several public and private companies, as well as, non-profit organization and focused on coordinating the reporting and management of the financial infrastructure for emerging growth businesses and organizations. In addition to serving on the board of several public, private and non-profit organizations, Mr. Brown has been the chairman of the audit committees of several public companies.   Mr. Brown graduated from the University of Southern California with a B.S. in Finance and earned the Chartered Financial Analyst (CFA) designation.  Mr. Brown is an Adjunct Professor in the Argyros School of Business & Finance at Chapman University where he teaches Entrepreneurial Finance.

The NLS-VPAC1 is a powerful tool to detect and visualize a variety of cancers at the earliest stage of disease.

 

 

Want to Learn More About NuView?

We welcome inquiries with interested individuals, media and potential investors. Please drop us a note in the contact form or call us directly.

Contact Address

NuView Life Sciences, Inc
1389 Center Drive, Suite 250
Park City, Utah 84098

Contact Details

TEL 888.902.7779
FAX 435.647.5602

Office Hours

9am to 5pm MST
Monday to Friday